Compare RDNT & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | BCPC |
|---|---|---|
| Founded | 1985 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.3B |
| IPO Year | 1996 | 1995 |
| Metric | RDNT | BCPC |
|---|---|---|
| Price | $76.05 | $166.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $82.80 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 632.3K | 139.4K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 20.87 |
| EPS | N/A | ★ 2.63 |
| Revenue | ★ $1,616,630,000.00 | $799,023,000.00 |
| Revenue This Year | $22.78 | $8.47 |
| Revenue Next Year | $10.70 | $4.89 |
| P/E Ratio | ★ N/A | $63.03 |
| Revenue Growth | 13.05 | ★ 13.56 |
| 52 Week Low | $50.82 | $139.17 |
| 52 Week High | $85.84 | $183.90 |
| Indicator | RDNT | BCPC |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 39.15 |
| Support Level | $69.96 | $159.54 |
| Resistance Level | $78.57 | $169.46 |
| Average True Range (ATR) | 2.55 | 3.43 |
| MACD | -0.07 | -0.97 |
| Stochastic Oscillator | 65.79 | 13.63 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.